comparemela.com

Latest Breaking News On - Fortress biotech company profile - Page 3 : comparemela.com

Fortress Biotech, Inc (NASDAQ:FBIOP) Announces $0 20 Monthly Dividend

Fortress Biotech, Inc. (NASDAQ:FBIOP – Get Free Report) announced a monthly dividend on Tuesday, January 9th, investing.com reports. Investors of record on Monday, January 15th will be given a dividend of 0.1953 per share on Wednesday, January 31st. This represents a $2.34 dividend on an annualized basis and a yield of 18.30%. The ex-dividend date […]

Fortress Biotech, Inc (FBIOP) to Issue Dividend of $0 20 on January 31st

Fortress Biotech, Inc. (NASDAQ:FBIOP – Get Free Report) announced a dividend on Tuesday, January 9th, investing.com reports. Stockholders of record on Friday, January 12th will be given a dividend of 0.1953 per share on Wednesday, January 31st. This represents a dividend yield of 19.37%. The ex-dividend date is Thursday, January 11th. Fortress Biotech Stock Down […]

Fortress Biotech, Inc (NASDAQ:FBIO) CEO Buys $2,664,775 50 in Stock

Fortress Biotech, Inc. (NASDAQ:FBIO – Get Free Report) CEO Lindsay A. Md Rosenwald acquired 1,567,515 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The shares were purchased at an average cost of $1.70 per share, for a total transaction of $2,664,775.50. Following the completion of the acquisition, the chief executive officer […]

Fortress Biotech (NASDAQ:FBIO) Receives New Coverage from Analysts at StockNews com

StockNews.com started coverage on shares of Fortress Biotech (NASDAQ:FBIO – Free Report) in a report published on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Separately, Cantor Fitzgerald reaffirmed an overweight rating and set a $75.00 price target on shares of Fortress Biotech in a research report on Tuesday, August […]

Fortress Biotech (NASDAQ:FBIO) Coverage Initiated at StockNews com

StockNews.com assumed coverage on shares of Fortress Biotech (NASDAQ:FBIO – Free Report) in a research report sent to investors on Friday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, Cantor Fitzgerald restated an overweight rating and set a $5.00 price target on shares of Fortress Biotech in a report on Tuesday, […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.